Blood lactate concentration in COVID-19: a systematic literature review
Abstract Coronavirus disease 2019 (COVID-19) is an infectious respiratory condition sustained by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which manifests prevalently as mild to moderate respiratory tract infection. Nevertheless, in a number of cases the clinical course may deteriorate, with onset of end organ injury, systemic dysfunction, thrombosis and ischemia. Given the clinical picture, baseline assessment and serial monitoring of blood lactate concentration may be conceivably useful in COVID-19. We hence performed a systematic literature review to explore the possible association between increased blood lactate levels, disease severity and mortality in COVID-19 patients, including comparison of lactate values between COVID-19 and non-COVID-19 patients. We carried out an electronic search in Medline and Scopus, using the keywords “COVID-19” OR “SARS-CoV-2” AND “lactate” OR “lactic acid” OR “hyperlactatemia”, between 2019 and present time (i.e. October 10, 2021), which allowed to identify 19 studies, totalling 6,459 patients. Overall, we found that COVID-19 patients with worse outcome tend to display higher lactate values than those with better outcome, although most COVID-19 patients in the studies included in our analysis did not have sustained baseline hyperlactatemia. Substantially elevated lactate values were neither consistently present in all COVID-19 patients who developed unfavourable clinical outcomes. These findings suggest that blood lactate monitoring upon admission and throughout hospitalization may be useful for early identification of higher risk of unfavourable COVID-19 illness progression, though therapeutic decisions based on using conventional hyperlactatemia cut-off values (i.e., 2.0 mmol/L) upon first evaluation may be inappropriate in patients with SARS-CoV-2 infection..
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:60 |
---|---|
Enthalten in: |
Clinical chemistry and laboratory medicine - 60(2021), 3 vom: 02. Dez., Seite 332-337 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Carpenè, Giovanni [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
Anmerkungen: |
© 2021 Walter de Gruyter GmbH, Berlin/Boston |
---|
doi: |
10.1515/cclm-2021-1115 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
OLC214298326X |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | OLC214298326X | ||
003 | DE-627 | ||
005 | 20231205151615.0 | ||
007 | tu | ||
008 | 230813s2021 xx ||||| 00| ||eng c | ||
024 | 7 | |a 10.1515/cclm-2021-1115 |2 doi | |
035 | |a (DE-627)OLC214298326X | ||
035 | |a (DE-B1597)cclm-2021-1115-p | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |a 540 |q VZ |
082 | 0 | 4 | |a 540 |a 610 |q VZ |
100 | 1 | |a Carpenè, Giovanni |e verfasserin |4 aut | |
245 | 1 | 0 | |a Blood lactate concentration in COVID-19: a systematic literature review |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a © 2021 Walter de Gruyter GmbH, Berlin/Boston | ||
520 | |a Abstract Coronavirus disease 2019 (COVID-19) is an infectious respiratory condition sustained by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which manifests prevalently as mild to moderate respiratory tract infection. Nevertheless, in a number of cases the clinical course may deteriorate, with onset of end organ injury, systemic dysfunction, thrombosis and ischemia. Given the clinical picture, baseline assessment and serial monitoring of blood lactate concentration may be conceivably useful in COVID-19. We hence performed a systematic literature review to explore the possible association between increased blood lactate levels, disease severity and mortality in COVID-19 patients, including comparison of lactate values between COVID-19 and non-COVID-19 patients. We carried out an electronic search in Medline and Scopus, using the keywords “COVID-19” OR “SARS-CoV-2” AND “lactate” OR “lactic acid” OR “hyperlactatemia”, between 2019 and present time (i.e. October 10, 2021), which allowed to identify 19 studies, totalling 6,459 patients. Overall, we found that COVID-19 patients with worse outcome tend to display higher lactate values than those with better outcome, although most COVID-19 patients in the studies included in our analysis did not have sustained baseline hyperlactatemia. Substantially elevated lactate values were neither consistently present in all COVID-19 patients who developed unfavourable clinical outcomes. These findings suggest that blood lactate monitoring upon admission and throughout hospitalization may be useful for early identification of higher risk of unfavourable COVID-19 illness progression, though therapeutic decisions based on using conventional hyperlactatemia cut-off values (i.e., 2.0 mmol/L) upon first evaluation may be inappropriate in patients with SARS-CoV-2 infection. | ||
700 | 1 | |a Onorato, Diletta |4 aut | |
700 | 1 | |a Nocini, Riccardo |4 aut | |
700 | 1 | |a Fortunato, Gianmarco |4 aut | |
700 | 1 | |a Rizk, John G. |0 (orcid)0000-0002-5216-8695 |4 aut | |
700 | 1 | |a Henry, Brandon M. |4 aut | |
700 | 1 | |a Lippi, Giuseppe |0 (orcid)0000-0001-9523-9054 |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Clinical chemistry and laboratory medicine |d De Gruyter, 1998 |g 60(2021), 3 vom: 02. Dez., Seite 332-337 |w (DE-627)240770250 |w (DE-600)1418007-8 |w (DE-576)064883795 |x 1434-6621 |7 nnns |
773 | 1 | 8 | |g volume:60 |g year:2021 |g number:3 |g day:02 |g month:12 |g pages:332-337 |
856 | 4 | 1 | |u https://doi.org/10.1515/cclm-2021-1115 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
912 | |a GBV_ILN_2006 | ||
912 | |a GBV_ILN_4219 | ||
912 | |a GBV_ILN_4277 | ||
951 | |a AR | ||
952 | |d 60 |j 2021 |e 3 |b 02 |c 12 |h 332-337 |